Search Within

Mrinal M Gounder

  1. "Head and Neck Service"
Formats
  1. Journal Article (7)
  2. Meeting Abstract (3)
  3. Research Letter (1)
Groups
  1. Department of Medicine (11)
  2. Head and Neck Service (11)
  3. Sarcoma Service (11)
  4. Solid Tumor Oncology Division (11)
  5. Department of Pathology and Laboratory Medicine (7)
  6. Epidemiology and Biostatistics (6)

More Groups

People
  1. Alan Ho (9)
  2. David Hyman (5)
  3. Marc Ladanyi (4)
  4. Martin Voss (4)
  5. Michael Berger (4)
  6. Alexander Shoushtari (3)

More People

Years
  1. 2020 (1)
  2. 2019 (1)
  3. 2018 (2)
  4. 2017 (5)
  5. 2016 (1)
  6. 2013 (1)
Publications
  1. Journal of Clinical Oncology (2)
  2. Annals of Oncology (1)
  3. British Journal of Cancer (1)
  4. Clinical Cancer Research (1)
  5. Human Pathology (1)
  6. Investigational New Drugs (1)

More Publications

Publishers
  1. American Society of Clinical Oncology (3)
  2. Nature Publishing Group (2)
  3. American Association for Cancer Research (1)
  4. Elsevier Inc. (1)
  5. Elsevier Science, Inc. (1)
  6. Nature Research (1)

More Publishers

Results (11)

Export to EndNote / Excel | PubMed

Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Genetic basis of SMARCB1 protein loss in 22 sinonasal carcinomas
    Journal Article

    Dogan, S.; Cotzia, P.; Ptashkin, R. N.; Nanjangud, G. J.; Xu, B.; Momeni Boroujeni, A.; Cohen, M. A.; Pfister, D. G.; Prasad, M. L.; Antonescu, C. R.; more...
    Human Pathology (2020)

    Fulltext@MSK | Save
  • Tumor mutational load predicts survival after immunotherapy across multiple cancer types
    Research Letter

    Samstein, R. M.; Lee, C. H.; Shoushtari, A. N.; Hellmann, M. D.; Shen, R.; Janjigian, Y. Y.; Barron, D. A.; Zehir, A.; Jordan, E. J.; Omuro, A.; more...
    Nature Genetics (2019)

    Fulltext@MSK | Save
  • Impact of race on dose selection of molecular-targeted agents in early-phase oncology trials
    Journal Article

    Yokota, T.; Bendell, J.; Lorusso, P.; Tsushima, T.; Desai, V.; Kenmotsu, H.; Watanabe, J.; Ono, A.; Murugesan, B.; Silva, J.; more...
    British Journal of Cancer (2018)

    Fulltext@MSK | Save
  • Genetic and histologic spectrum of SMARCB1-deficient carcinomas of the head and neck including sinonasal tract, thyroid and skin
    Meeting Abstract

    Cotzia, P.; Ptashkin, R.; Gounder, M. M.; Pfister, D. G.; Berger, M. F.; Ladanyi, M.; Ghossein, R.; Antonescu, C. R.; Dogan, S.
    Modern Pathology (2018)

    Fulltext@MSK | Save
  • OncoKB: A precision oncology knowledge base
    Journal Article

    Chakravarty, D.; Gao, J.; Phillips, S.; Kundra, R.; Zhang, H.; Wang, J.; Rudolph, J. E.; Yaeger, R.; Soumerai, T.; Nissan, M. H.; more...
    JCO Precision Oncology (2017)

    Fulltext@MSK | Save
  • A call for global harmonization of phase I oncology trials: Results from two parallel, first in-human phase I studies of DS-7423, an oral PI3K/mTOR dual inhibitor in advanced solid tumors conducted in the United States and Japan
    Meeting Abstract

    Yokota, T.; Bendell, J. C.; LoRusso, P.; Tsushima, T.; Desai, V.; Kenmotsu, H.; Watanabe, J.; Ono, A.; Murugesan, B. G.; Silva, J.; more...
    Journal of Clinical Oncology (2017)

    Fulltext@MSK | Save
  • Clinical and morphologic characteristics of MEK inhibitor - Associated retinopathy: Differences from central serous chorioretinopathy
    Journal Article

    Francis, J. H.; Habib, L. A.; Abramson, D. H.; Yannuzzi, L. A.; Heinemann, M.; Gounder, M. M.; Grisham, R. N.; Postow, M. A.; Shoushtari, A. N.; Chi, P.; more...
    Ophthalmology (2017)

    Fulltext@MSK | Save
  • A phase 1b dose expansion study of the pan-class I PI3K inhibitor buparlisib (BKM120) plus carboplatin and paclitaxel in PTEN deficient tumors and with dose intensified carboplatin and paclitaxel
    Journal Article

    Smyth, L. M.; Monson, K. R.; Jhaveri, K.; Drilon, A.; Li, B. T.; Abida, W.; Iyer, G.; Gerecitano, J. F.; Gounder, M.; Harding, J. J.; more...
    Investigational New Drugs (2017)

    Fulltext@MSK | Save
  • The PARP inhibitor veliparib can be safely added to bendamustine and rituximab and has preliminary evidence of activity in B-cell lymphoma
    Journal Article

    Soumerai, J. D.; Zelenetz, A. D.; Moskowitz, C. H.; Palomba, M. L.; Hamlin, P. A. Jr; Noy, A.; Straus, D. J.; Moskowitz, A. J.; Younes, A.; Matasar, M. J.; more...
    Clinical Cancer Research (2017)

    Fulltext@MSK | Save
  • What hides behind the MASC: Clinical response and acquired resistance to entrectinib after ETV6-NTRK3 identification in a mammary analogue secretory carcinoma (MASC)
    Journal Article

    Drilon, A.; Li, G.; Dogan, S.; Gounder, M.; Shen, R.; Arcila, M.; Wang, L.; Hyman, D. M.; Hechtman, J.; Wei, G.; more...
    Annals of Oncology (2016)

    Fulltext@MSK | Save